Latest News for: 003

Edit

NISN-2026-003 Emergency Power Off (EPOs) (Northern Ireland Executive)

Public Technologies 09 Oct 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 135059481) .
Edit

Classified 10.08.2026 E.003.4

Rainy Lake Gazette 08 Oct 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=RLGBrd_COM-TheExtraTMC_10-08-2026_CLASSIFIED_E_003_4 ....
Edit

Classified 10.07.2026 A.003.1

The Chronicle-News 07 Oct 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=TRITab_COM-ChronicleNews_10-07-2026_CLASSIFIED_A_003_1 ....
Edit

Front Range Pharmaceuticals Announces FDA Clearance to Initiate Phase 2 Trial of FRP-003 in Long COVID

Hastings Tribune 06 Oct 2026
DENVER--(BUSINESS WIRE)--Oct 6, 2026-- ... .
Edit

Classified 10.05.2026 A.003.4

The Chronicle-News 05 Oct 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=TRITab_COM-ChronicleNews_10-05-2026_CLASSIFIED_A_003_4 ....
Edit

Request to join a pre-qualified supplier panel for - PQS26-003 Soils and Mulches (City of Busselton)

Public Technologies 05 Oct 2026
) Request to join a pre-qualified supplier panel for - PQS26-003 Soils and Mulches. Published on Monday, 5 October 2026 at 10.09.01 AM ... The lowest or any tender will not necessarily be accepted ... Annie Riodran. CHIEF EXECUTIVE OFFICER. Images ... Disclaimer.
Edit

Classified 10.01.2026 E.003.4

Rainy Lake Gazette 01 Oct 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=RLGBrd_COM-TheExtraTMC_10-01-2026_CLASSIFIED_E_003_4 ....
Edit

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study (Fund + NV)

Public Technologies 01 Oct 2026
) EGL-003, a selective IL-2 agonist, was well tolerated across all four dose cohorts. EGL-003 produced selective, dose-dependent Treg expansion without amplification of conventional CD4, CD8 or NK cell populations ... About EGL-003.
Edit

Classified 09.30.2026 A.003.4

The Chronicle-News 30 Sep 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=TRITab_COM-ChronicleNews_09-30-2026_CLASSIFIED_A_003_4 ....
Edit

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg ...

Nasdaq Globe Newswire 30 Sep 2026
... 1 single ascending dose (SAD) study in healthy volunteers of EGL-003, the company’s Treg-selective interleukin-2 (IL-2) agonist being developed for autoimmune diseases, including atopic dermatitis.
Edit

BNG USD 50mn Tap of SOFR FRNs due 17 Mar 2028 Final Terms (EV) (003) (004) (BNG Bank NV)

Public Technologies 29 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134787268) .
Edit

REPORT on the proposal for a decision of the European Parliament and of the Council on the mobilisation of the European Globalisation Adjustment Fund for Displaced Workers following an application from Finland – EGF/2026/003 FI/Valmet Automotive (European Parliament)

Public Technologies 29 Sep 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 134795876) .
Edit

Classified 09.28.2026 A.003.4

The Chronicle-News 28 Sep 2026
Single View. Page 1 / -. Loading. ×. pdf.php?file=TRITab_COM-ChronicleNews_09-28-2026_CLASSIFIED_A_003_4 ....
Edit

Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma

Nasdaq Globe Newswire 25 Sep 2026
... 2 INFLECTION-003 clinical study triggering the release of the second tranche of financing.
Edit

September 25, 2026 KASE Index increased by 0.003% to 7,786.09 (KASE - Kazakhstan Stock Exchange JSC)

Public Technologies 25 Sep 2026
) September 25, 2026 KASE Index increased by 0.003% to 7,786.09. /KASE, September 25, 2026/ - By shares trading results on Kazakhstan Stock Exchange (KASE) on September 25, 2026, KASE Index increased by 0.26 points (0.003%) from 7,785.83 to 7,786.09.

Article Search

tools
×
×
×
×